Literature DB >> 10368196

Effect of transurethral electrovaporization of the prostate on serum prostate specific antigen concentration.

S Küpeli1, T Soygür, E Yilmaz, S Aytaç.   

Abstract

OBJECTIVE: To assess the effect of transurethral electrovaporization of the prostate (TUVP) on serum prostate specific antigen (PSA) concentration. PATIENTS AND METHODS: Twenty-five men (mean age 61.7 years) with symptoms of prostatism underwent TUVP. Serum PSA levels were determined before any prostatic manipulation, and again at 1 and 24 h after TUVP. In the first 6 weeks after TUVP, serum PSA was measured every week. Prostatic size was measured by transrectal ultrasonography before and again at 6 weeks after TUVP.
RESULTS: The mean serum PSA concentration was significantly higher at 1 and 24 h after TUVP (P<0.001) than before. The PSA level returned to less than the value before TUVP at 2, 3 and 4 weeks afterwards in eight (32%), 13 (52%) and 20 (80%) patients, respectively; five (20%) patients reached the baseline value 6 weeks after TUVP. The mean reduction in prostatic volume 6 weeks after TUVP was 42% and the reduction in tissue volume was significantly correlated with the decrease in serum PSA concentration at 6 weeks (P<0.05).
CONCLUSION: TUVP increases serum PSA levels, the transient elevation persisting for up to 6 weeks but then declining to a stable, low PSA concentration. Therefore, it is important to wait at least 6 weeks to obtain an accurate and meaningful serum PSA level after TUVP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368196     DOI: 10.1046/j.1464-410x.1999.00002.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  3 in total

1.  Changes of serum prostate-specific antigen following high energy thick loop prostatectomy.

Authors:  R F Talic; A M El-Tiraifi; S Altaf; T B Hargreave
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

2.  Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.

Authors:  Hiral Patel; Rosemarie Mick; Jarod Finlay; Timothy C Zhu; Elizabeth Rickter; Keith A Cengel; S Bruce Malkowicz; Stephen M Hahn; Theresa M Busch
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 3.  Photosensitizers in prostate cancer therapy.

Authors:  Taher Gheewala; Troy Skwor; Gnanasekar Munirathinam
Journal:  Oncotarget       Date:  2017-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.